Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in anti-PD-1-resistant recurrent or advanced non-small cell lung cancer
jRCTs031180055Completed
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Objective response rate. Started Dec 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180055.